CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. | The deal allows CSL to ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
The FDA has flagged J&J Medtech’s recall of its Cerepak detachable coils as Class I in the wake of one death and four serious injuries. | The FDA has flagged J&J Medtech’s recall of Cerepak detachable ...
After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multi-year deal to access Iambic Therapeutics' broad suite of | ...
Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. | Eli Lilly ...
When Expertise, Monitoring, Systems, and AI AlignBy Amir Malka, CEO, Bioforum The Data Masters | Trial oversight is shifting ...
Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...
AI is no longer a future concept in life sciences — it is actively reshaping how clinical trials are designed, executed and ...
Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...
Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...
Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results